Peter Blume-Jensen

Insider Reports History

Location
Watertown, MA
Signature
/s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Peter Blume-Jensen:

Company Role Class Num Shares Value Price $ Report Date Ownership
Acrivon Therapeutics, Inc. President and CEO, Director Common Stock 2,080,204 $3,182,712 $1.53 21 Feb 2026 Direct
Acrivon Therapeutics, Inc. President and CEO, Director Common Stock 314,127 $609,406 $1.94 21 Feb 2026 Indirect
Acrivon Therapeutics, Inc. President and CEO, Director Stock Option (Right to Buy) 390,390 01 Mar 2025 Direct
Acrivon Therapeutics, Inc. President and CEO, Director Stock Option (Right to Buy) 140,540 01 Mar 2025 Indirect

Insider Reports Filed by Peter Blume-Jensen

Symbol Company Period Transactions Value $ Form Type Role Filing Time
ACRV Acrivon Therapeutics, Inc. 21 Feb 2026 1 -$21,825 4 President and CEO, Director 24 Feb 2026, 16:12
ACRV Acrivon Therapeutics, Inc. 14 Feb 2026 2 -$3,066 4 President and CEO, Director 18 Feb 2026, 16:09
ACRV Acrivon Therapeutics, Inc. 14 Jan 2026 1 +$82,124 4 President and CEO, Director 16 Jan 2026, 16:02
ACRV Acrivon Therapeutics, Inc. 21 Nov 2025 1 -$45,779 4 President and CEO, Director 25 Nov 2025, 16:03
ACRV Acrivon Therapeutics, Inc. 14 Nov 2025 2 -$134,971 4 President and CEO, Director 18 Nov 2025, 16:28
ACRV Acrivon Therapeutics, Inc. 21 Aug 2025 1 -$26,275 4 President and CEO, Director 25 Aug 2025, 16:39
ACRV Acrivon Therapeutics, Inc. 14 Aug 2025 2 -$83,756 4 President and CEO, Director 18 Aug 2025, 17:14
ACRV Acrivon Therapeutics, Inc. 21 May 2025 1 -$22,890 4 President and CEO, Director 23 May 2025, 16:58
ACRV Acrivon Therapeutics, Inc. 14 May 2025 2 -$68,693 4 President and CEO, Director 16 May 2025, 16:16
ACRV Acrivon Therapeutics, Inc. 01 Mar 2025 2 $0 4 President and CEO, Director 04 Mar 2025, 17:11
ACRV Acrivon Therapeutics, Inc. 21 Feb 2025 1 -$110,268 4 President and CEO, Director 25 Feb 2025, 16:09
ACRV Acrivon Therapeutics, Inc. 14 Feb 2025 2 -$204,502 4 President and CEO, Director 19 Feb 2025, 16:52
ACRV Acrivon Therapeutics, Inc. 21 Nov 2024 1 -$128,220 4 President and CEO, Director 25 Nov 2024, 16:29
ACRV Acrivon Therapeutics, Inc. 14 Nov 2024 2 -$477,228 4 President and CEO, Director 18 Nov 2024, 16:26
ACRV Acrivon Therapeutics, Inc. 21 Aug 2024 1 -$731,671 4 President and CEO, Director 23 Aug 2024, 16:11
ACRV Acrivon Therapeutics, Inc. 14 Aug 2024 1 -$419,550 4 President and CEO, Director 16 Aug 2024, 16:47
ACRV Acrivon Therapeutics, Inc. 14 May 2024 1 -$459,114 4 President and CEO, Director 16 May 2024, 18:54
ACRV Acrivon Therapeutics, Inc. 01 Mar 2024 2 $0 4 President and CEO, Director 27 Nov 2024, 18:04
ACRV Acrivon Therapeutics, Inc. 14 Feb 2024 1 -$142,327 4 President and CEO, Director 16 Feb 2024, 17:06
ACRV Acrivon Therapeutics, Inc. 14 Nov 2023 1 -$1,214,237 4 President and CEO, Director 16 Nov 2023, 19:41
ACRV Acrivon Therapeutics, Inc. 21 Aug 2023 1 $0 4 President and CEO, Director 23 Aug 2023, 16:19
ACRV Acrivon Therapeutics, Inc. 31 May 2023 2 +$130,387 4 President and CEO, Director 01 Jun 2023, 20:40
ACRV Acrivon Therapeutics, Inc. 14 Nov 2022 6 $0 4 President and CEO, Director 16 Nov 2022, 18:05
ACRV Acrivon Therapeutics, Inc. 09 Nov 2022 0 $0 3 President and CEO, Director 09 Nov 2022, 19:30